Eczema (Atopic Dermatitis): Flare Severity Bands, Corticosteroid Steps & Barrier Repair

Eczema is a clinical and pathological term for an inflammatory skin disorder characterised by spongiosis (intra-epidermal oedema), pruritus and a recurrent course. The words eczema and dermatitis are used interchangeably in most English-language guidance, with atopic eczema accounting for the majority of consultations and the remaining workload split between contact, nummular, dyshidrotic, seborrhoeic and stasis variants.

Pathophysiology converges on a common theme: a compromised epidermal barrier (often via filaggrin pathway changes in atopic disease), exaggerated type-2 immune signalling with interleukin-4, -13 and -31, mast-cell and neuronal itch amplification, and dysbiosis of the cutaneous microbiome with frequent Staphylococcus aureus overgrowth on lesional skin. The relative weight of barrier failure, immune drive and external trigger differs by subtype, which is why nursing assessment that maps lesion distribution and provoking exposure—not morphology alone—drives sensible therapy.

Use this grid at handover or triage so the right subtype anchors the right management lane. The therapeutic ladder is similar across types, but the trigger workup and referral target differ.

↔On a small screen, swipe or scroll sideways to see the full table.

Practice note: erythema reads differently on richly pigmented skin—violaceous, grey or post-inflammatory hyper- or hypopigmentation can dominate; rely on texture, distribution, secondary changes and patient-reported itching rather than colour intensity alone.

Across subtypes, itch leads the history—often worse at night—and drives excoriations that perpetuate the inflammation. Acute flares show erythema, papules and vesicles with weeping; subacute disease shows scaling and crusting; chronic disease shows lichenification, fissuring and pigmentary change.

Typical features

• Pruritus that disturbs sleep (link to insomnia) and degrades school or work performance.
• Recurring eczematous patches in characteristic distribution for the suspected subtype.
• Xerosis between flares with seasonal worsening in low humidity.
• Secondary changes: lichenification, hyperpigmentation, palmar hyperlinearity, Dennie–Morgan infraorbital folds.

Atypical or under-recognised presentations

• Follicular or papular morphology with limited erythema in patients with darker skin tones; severity is easily under-scored.
• Isolated eyelid, lip or nipple eczema in adults—suspect contactant overlay (cosmetic, fragrance, latex).
• Hand-only disease in occupational contexts (healthcare, hairdressing, food handling) with both irritant and allergic drivers in the same patient.
• Bilateral lower-leg disease misread as recurrent rash infection when the underlying problem is venous stasis.

Eczema arises from interaction between a permissive host (genes, immunity, vasculature) and external load (irritants, allergens, microbes, mechanical injury, oedema). Subtypes weight these differently.

Host factors

• Filaggrin loss-of-function variants and other barrier-protein polymorphisms predisposing to atopic disease.
• Family history of atopy (eczema, asthma, allergic rhinitis, food allergy).
• Type-2 immune skewing with elevated IL-4/IL-13/IL-31 signalling.
• Chronic venous insufficiency, lymphoedema or right heart failure driving stasis subtypes.

External / modifiable amplifiers

• Soap, detergent, solvent and fragrance exposure—both occupational and domestic.
• Hot showers, low ambient humidity and harsh fabrics.
• Allergen sensitisers (nickel, hair dye, rubber accelerators, preservatives) confirmed by patch testing.
• Mechanical scratch trauma and incomplete sleep recovery feeding the itch–scratch–lichenification cycle.
• Microbial drivers: S. aureus colonisation in flares; Malassezia overgrowth in seborrhoeic disease.

Clinical assessment

Diagnosis is clinical for the great majority of eczema presentations. Nurses contribute structured skin assessment, body-surface mapping, trigger and occupational history, an admission assessment noting medication and allergy reconciliation, and validated severity scoring (POEM, NRS itch, EASI or SCORAD where teams are trained).

Laboratory investigations

• No routine bloods are required for typical eczema. The AAD Choosing Wisely campaign explicitly cautions against skin prick tests or RAST-style serum panels as a screen for eczema.
• Targeted IgE or specific IgE testing is reasonable when clinically suspected food allergy, asthma comorbidity or contact urticaria pathways are being formally evaluated.
• Skin culture is helpful when impetiginisation, recurrent furunculosis or treatment-resistant crusting raises questions about resistant S. aureus.
• Inflammatory markers (CRP, white cell count) in suspected systemic infection—not as a routine eczema panel.

Imaging

Imaging is not part of routine eczema diagnosis. Doppler ultrasound of the lower limb supports stasis dermatitis evaluation when chronic venous insufficiency is suspected and compression therapy is being planned.

Diagnostic criteria and severity tools

UK paediatric guidance anchors atopic eczema diagnosis on visible skin involvement plus three or more of: a personal history of flexural involvement, history of asthma or hay fever (or first-degree relative for under-fours), generally dry skin in the past year, onset under age two and visible flexural eczema. Severity in clinics typically combines a physical score (EASI or SCORAD) with a patient-reported tool (POEM) and quality-of-life impact.

Eczema mimics are common and the cost of mislabel is months of ineffective topical therapy or unnecessary antibiotic courses. Compare distribution, tempo and response to a structured emollient–steroid trial before committing to long-term ultra-potent regimens.

↔On a small screen, swipe or scroll sideways to see the full table.

Therapy is layered: barrier repair, anti-inflammatory topicals, adjunct antipruritics, antimicrobial care when indicated, treatment of subtype-specific drivers (compression for stasis, allergen avoidance for contact disease), and—through specialists—phototherapy, conventional immunosuppressants, biologics or JAK inhibitors. Doses below are illustrative; dispense per local formulary and prescriber direction.

First-line management

• Emollients as the foundation: ointment-style vehicles for very dry skin, generous quantities, used as soap substitutes too. NICE quality standards expect liberal, frequent use during flares and remission.
• Topical corticosteroids (TCS) matched to site and severity—e.g. hydrocortisone 1% on face/flexures; mid-potency mometasone on body for moderate flares. Counsel fingertip-unit dosing and review at one to two weeks.
• Topical calcineurin inhibitors (TCI): tacrolimus ointment for sensitive sites or steroid-sparing maintenance per dermatology plans.
• Bath and shower modifications: short, lukewarm, soap-substitute washes; pat-dry; emollient within minutes of getting out.
• Non-sedating antihistamines (e.g. cetirizine or loratadine) only when concomitant urticaria or rhinitis exists—not as routine eczema therapy.
• Sleep-rescue sedating antihistamines such as diphenhydramine in short courses when itch disrupts sleep, per CKS/NICE guidance.

Second-line and specialist options

• Phototherapy (narrowband UVB) under dermatology governance for moderate–severe atopic, nummular or dyshidrotic disease unresponsive to topicals.
• Wet-wrap therapy and dilute bleach baths as protocolised adjuncts for moderate–severe disease with recurrent infection.
• Conventional systemic immunomodulators: cyclosporine, methotrexate, azathioprine or mycophenolate when topical regimens are optimised yet quality of life remains harmed.
• Targeted biologics and small molecules: dupilumab, tralokinumab and lebrikizumab (IL-4/13 axis), nemolizumab (IL-31), and oral JAK inhibitors (baricitinib, upadacitinib, abrocitinib) as commissioning permits, with formal severity criteria and monitoring labs.
• Antiviral therapy with acyclovir for confirmed or strongly suspected eczema herpeticum, escalated by physicians per local protocol.
• Short courses of oral prednisone may bridge severe flares to slower-acting therapy; avoid as long-term control (AAD Choosing Wisely caution).

Subtype-specific notes

• Contact dermatitis: identification and avoidance of the causative allergen via dermatology-led patch testing is the core therapeutic move; topical steroids treat the inflammatory residue.
• Stasis dermatitis: compression therapy (when arterial supply is adequate), leg elevation, treatment of venous insufficiency, plus topical steroid for the inflammatory phase—not antibiotics unless cellulitis is genuinely present.
• Dyshidrotic eczema: short bursts of higher-potency topical steroid on palms and soles; mind sweat-trapping gloves and stress drivers.
• Seborrhoeic dermatitis: ketoconazole, selenium sulphide or zinc pyrithione shampoos with adequate scalp contact; short topical steroid bursts for inflamed flares.

Special populations

• Infants and young children: emphasise gentle cleansing, distraction for scratching and infection surveillance; potency ceilings and durations follow paediatric dermatology guidance.
• Pregnancy and lactation: low–moderate potency TCS on limited areas is generally acceptable; avoid systemic retinoids; coordinate any systemic therapy with obstetrics and pharmacy.
• Older adults with stasis disease: screen for arterial disease before applying compression; falls precaution and skin tear vigilance during dressing changes.
• Coexisting airway atopy: continue inhaled regimens or montelukast exactly as prescribed—skin and lung type-2 disease share biology but need separate monitoring.

Operationalise a repeatable loop in clinic, ward and community: quantify itch and sleep, inspect for infection, reconcile topical technique, then re-set the escalation clock.

• Monitoring cadence: review topical changes at one to two weeks for children (per NICE); adults follow dermatology-defined intervals but use the same trigger list (vesicles, fever, ocular pain) for earlier review.
• Treatment-failure flags: POEM stagnation despite documented adherence, new pain or pustulation, widespread sleep loss, or psychological deterioration—escalate rather than adding more steroid.
• Drug interactions: cyclosporine and tacrolimus are CYP3A4 substrates—pharmacist verification before starting macrolides, azole antifungals or grapefruit-rich diets.
• Referral thresholds: diagnostic uncertainty, erythroderma, suspected eczema herpeticum, occupational disability, recurrent contact dermatitis without a clear allergen, severe psychological impact, or stasis dermatitis with non-healing ulceration.
• Documentation: serial photography (with consent), POEM/NRS scores, fingertip-unit teaching captured in record so escalation reviewers see objective data, not just narrative.

Decision flow (shift-ready)

1. New monomorphic vesicles ± fever → urgent senior review for possible eczema herpeticum, antiviral pathway.
2. Spreading warmth, lymphangitis, sepsis criteria → manage as bacterial soft-tissue infection, swab where clinically indicated, escalate per protocol.
3. Bilateral lower-leg eczema with oedema → think stasis: compression workup, vascular assessment, topical anti-inflammatory rather than antibiotics by default.
4. Stable flare with intact sleep → reinforce emollient and prescribed TCS or TCI, book 10–14 day review and document POEM score.
5. POEM unchanged despite full adherence → flag for systemic or biologic discussion, not endless potency stacking.

Bedside monitoring checklist

• Temperature, heart rate and CRP trend when bacterial superinfection is suspected.
• Pain disproportionate to visible flare—prompt for herpetic infection workup.
• Limb circumference and pulses where stasis disease and compression are in play.
• Sleep diary and validated itch score across visits, not just at first contact.
• Blood pressure, renal function and lipid trend if a systemic immunomodulator is started.

• Bacterial superinfection (impetiginisation, deeper soft-tissue infection) and rarely bacteraemia from extensive skin breakdown.
• Viral superinfection—herpes simplex (eczema herpeticum) most feared; molluscum contagiosum sometimes widespread.
• Ocular complications including blepharitis, conjunctivitis and—rarely—keratoconjunctivitis with chronic facial disease.
• Allergic contact sensitisation to topical antibiotics, fragrances or preservatives layered onto chronic eczema (especially in stasis disease).
• Sleep deprivation, school or work absenteeism, anxiety and depressive symptoms—document via validated tools so they appear in MDT reviews.
• Topical corticosteroid adverse effects: cutaneous atrophy, telangiectasia, striae, perioral dermatitis, rebound flare on abrupt cessation.
• Stasis dermatitis complications: venous ulceration, lipodermatosclerosis, recurrent swelling and contact dermatitis from topical agents.

Prevention here is clinician-facing, not lifestyle filler: proactive barrier maintenance during remission with continued emollient quantities; trigger audits for occupational and domestic irritants; pre-emptive twice-weekly TCS or TCI to recurrence-prone sites where dermatology has authorised this maintenance approach; influenza and other indicated vaccinations on schedule for systemically immunosuppressed patients; compression and venous review for patients prone to stasis disease; and structured patient education that includes pump-dispenser hygiene to reduce contamination of shared emollient pots.

Most childhood-onset atopic eczema improves through adolescence, although a substantial minority—often quoted as one in three or so—continue to flare into adult life and many retain sensitive skin. Contact dermatitis often resolves entirely once the trigger is identified and avoided. Nummular and dyshidrotic disease tend to relapse but respond well to short, well-targeted topical bursts. Stasis dermatitis is a chronic process tied to venous health; without compression and vascular care, it progresses to ulceration. Realistic counselling beats overpromise: control, not cure, is the usual frame.

Technique coaching

Show patients and caregivers how to apply emollients in the direction of hair growth, wait for absorption before sequencing topical steroids if the prescribing plan separates them, and use cotton gloves at night when scratching tears the skin. Demonstrate the fingertip unit on your own hand—measurement beats memory.

Equity and literacy

Translate steroid potencies and vehicle differences into plain language; address steroid phobia openly with reassurance grounded in time-limited, site-appropriate use; supply pump dispensers for shared households to reduce pot contamination flagged by NHS safety briefings.

Mental health

Routine eczema visits should screen for sleep loss and mood symptoms; chronic visible disease overlaps with depression and anxiety disorders—document and refer where local pathways exist.

Escalation triggers

• Sudden vesiculation with fever or eye pain—suspect eczema herpeticum.
• Spreading warmth, fever or sepsis criteria—treat as bacterial soft-tissue infection.
• Fever with rash in immunosuppressed or biologic-treated patients—lower threshold for review.
• Erythroderma with thermoregulatory or haemodynamic instability—admit and call dermatology and acute medicine together.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of atopic eczema, structured emollient + topical-corticosteroid potency ladder + topical calcineurin inhibitors, systemic options (dupilumab, JAK inhibitors) for severe disease and the eczema-herpeticum / bacterial-superinfection / paediatric red flags.